Kamari Pharma key facts
as of Oct 2026- Developer of a bio-pharmaceutical platform designed to develop proprietary small-molecule inhibitors.
- Kamari Pharma is valued at approximately $42.8M as of Oct 2026 (last reported valuation).
- It has raised $48.0M; the latest was Later Stage VC ($23.0M) in Jun 2025.
- Notable investors include Arkin Capital, Wille Finance, BRM Group, Guangzhou Sino-Israel Bio-Industry Investment Fund, Pontifax Venture Capital.
- Status: Privately Held (backing).
Kamari Pharma's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·Watch Kamari Pharma: the Monday email on marks, rounds and moves
Kamari Pharma funding rounds
No funding rounds for Kamari Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kamari Pharma valuation
Kamari Pharma's last reported valuation was $42.8 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Kamari Pharma investors
5 investors are on record for Kamari Pharma, including Arkin Capital, Wille Finance, BRM Group and Guangzhou Sino-Israel Bio-Industry Investment Fund.
About Kamari Pharma
Developer of a bio-pharmaceutical platform designed to develop proprietary small-molecule inhibitors. The company's platform uses a scientific approach to treat conditions of the skin with no current treatments by targeting the root cause of serum calcium dysregulation, enabling patients to get treatment for various dermatological conditions.
- Sector
- Healthcare
- HQ
- Ness Ziona, Israel
- Founded
- 2018
- Employees
- 8
- Website
- kamaripharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.